. Author manuscript; available in PMC: 2011 May 1.

Published in final edited form as: Clin Infect Dis. 2010 May 1;50(9):1258–1267. doi: 10.1086/651603

Table 2. RSV fusion inhibitors.

Compound	Company	^a F1 Interaction	Structure	Route of administration	Sub-group	Model	Reference
TMC-353121	Johnson & Johnson/Tibotec	Hydrophobic cavity on ^bHR1 surface of ^c6HB	Benzimidazole derivatives	Inhaled/oral	A/B	Cotton rat	[56, 108, 109]
VP-14637	ViroPharma Inc/RSVCO	Hydrophobic cavity on HR1 surface of 6HB; similar mechanism to TMC-353121	Triphenolic compound	Inhaled	A/B	Cotton rat/humans	[56, 110, 111, 120]
BMS-433771	Bristol-Myers Squibb	Hydrophobic cavity on surface of HR1 trimeric coiled-coil	Benzimidazole derivatives	Oral	A/B	Cotton rat/mice	[110, 121]
RFI-641	Wyeth Research	Interacts with F-protein in its native state	Disulfonated stilbene	Inhaled	A/B	Mice/African green monkeys/humans	[122]
BTA9881	Biota Holdings Limited/AstraZeneca	Inhibition of F protein assumed based on inhibition of syncytium formation	Imidazoiso-indolone derivative	Oral	A/B	Rodents/humans	[123, 124]

F1 - Fusion 1 protein; HR – Heptad repeat; 6HB – Six-helix bundle.